lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
887 rows where filing_year = 2015 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1655795 | AMERICAN COLLEGE OF CLINICAL PHARMACY dc2e1c42-7138-4760-9870-6ed2ed91fe95 | Q1 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2015 | first_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 127250 | 0 | 0 | 2015-04-01T15:37:41.410000-04:00 | |
| 1656211 | ACADEMY OF MANAGED CARE PHARMACY 79a8cd80-ef0b-413d-8634-03106883b197 | Q1 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2015 | first_quarter | PHA | Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy | Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 219000 | 0 | 0 | 2015-04-04T17:21:53.030000-04:00 | |
| 1656266 | ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) ab065e6a-f821-4d37-9532-db8d8c0531f4 | Q1 | ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) | 400637926 | ANAZAOHEALTH CORPORATION | 2015 | first_quarter | PHA | Issues related to the practice of Compounding Pharmacy, DQSA | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 22500 | 0 | 0 | 2015-04-06T09:37:40.480000-04:00 | |
| 1656268 | ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) 6d82d5d9-34ed-4996-9fb3-2e7245d8bd2c | Q1 | ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) | 400637926 | PHYSICIAN SPECIALTY COMPOUNDING | 2015 | first_quarter | PHA | Issues related to the practice of Compounding Pharmacy, the DQSA | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2015-04-06T09:40:42.713000-04:00 | |
| 1656270 | ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) 828d5e6c-ceaa-4078-9db4-dd59e17027b1 | Q1 | ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) | 400637926 | ROCK & ASSOCIATES | 2015 | first_quarter | PHA | Issues related to Compounding Pharmacy, the DQSA | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2015-04-06T09:42:45.263000-04:00 | |
| 1656713 | MR. THEODORE (TED) JONES cee09d17-f986-40af-8149-76f5c13e0bc9 | Q1 | MR. THEODORE (TED) JONES | 20926 | COQUI RADIOPHARMACEUTICALS, CORP. | 2015 | first_quarter | PHA | American Medical Isotopes Production Act of 2012 that was contained in the National Defense Authorization Act for Fiscal Year 2013. Acceleration of production of 99 MO using LEU (Low Enriched Uranium). | HOUSE OF REPRESENTATIVES,SENATE | 39193 | 0 | 0 | 2015-04-07T12:01:59.220000-04:00 | |
| 1656779 | ROCK & ASSOCIATES 458e11f9-d2dc-4fb8-b55c-a75ce6e884c7 | Q1 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2015 | first_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-04-07T14:22:22.113000-04:00 | |
| 1656785 | ROCK & ASSOCIATES 3b6b8351-760d-430e-b376-4693237652bf | Q1 | ROCK & ASSOCIATES | 33545 | CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY) | 2015 | first_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2015-04-07T14:31:25.677000-04:00 | ||
| 1656794 | ROCK & ASSOCIATES 7a4f5ade-f773-4190-9d59-16cc094b8d40 | Q1 | ROCK & ASSOCIATES | 33545 | DIAMONDBACK DRUGS | 2015 | first_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-04-07T14:37:29.897000-04:00 | |
| 1656863 | NELSON MULLINS RILEY & SCARBOROUGH 989ed5d8-7eeb-4344-89d0-a8e7f0b06d24 | Q1 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) | 2015 | first_quarter | PHA | Any legislation and regulation to the treatment of opioid abuse. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2015-04-07T15:35:23.730000-04:00 | |
| 1656901 | ROCK & ASSOCIATES 3fbbe57e-90b0-4aef-9c76-aa610c02d3c9 | Q1 | ROCK & ASSOCIATES | 33545 | TOWN & COUNTRY COMPOUNDING AND CONSULTING | 2015 | first_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-04-07T15:58:48.740000-04:00 | |
| 1656916 | ROCK & ASSOCIATES 0361022b-c989-4e7a-ada4-281090cf65dc | Q1 | ROCK & ASSOCIATES | 33545 | US COMPOUNDING | 2015 | first_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-04-07T16:07:57.850000-04:00 | |
| 1656928 | ROCK & ASSOCIATES 03739736-356e-4621-815a-c22d81c098ba | Q1 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2015 | first_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-04-07T16:14:05.290000-04:00 | |
| 1656938 | ROCK & ASSOCIATES 4bd2cd74-49b9-40aa-893a-620bbeb716df | Q1 | ROCK & ASSOCIATES | 33545 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2015 | first_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-04-07T16:20:10.417000-04:00 | |
| 1656953 | ROCK & ASSOCIATES dad2fcb5-ade2-44cc-af00-3851754e8a0c | Q1 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2015 | first_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2015-04-07T16:27:20.297000-04:00 | |
| 1657444 | THE MATHIS HARPLE GROUP fb742eed-fbb5-416a-a27b-f6fdf6ea0b3f | Q1 | THE MATHIS HARPLE GROUP | 322911 | PILMA | 2015 | first_quarter | PHA | Patent Protection; Medicare Part D; Trans-Pacific Partnership; 12 Year Data Exclusivity | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2015-04-08T16:44:58.997000-04:00 | |
| 1657545 | CAPITALHILL ADVISORY e7ca1bcd-193e-419f-9867-6d2e353d9df0 | Q1 | CAPITALHILL ADVISORY | 401103351 | ASTRAZENECA PTY LIMITED | 2015 | first_quarter | PHA | Australian government policy on intellectual property and its impact on the Australian healthcare system | State, Dept of (DOS) | 0 | 0 | 2015-04-08T23:21:12.580000-04:00 | ||
| 1657547 | CAPITALHILL ADVISORY 630dd0dc-ef9b-4272-8563-21312b5416f4 | Q1 | CAPITALHILL ADVISORY | 401103351 | NOVARTIS PHARMACEUTICALS PTY LTD ( AUSTRALIA) | 2015 | first_quarter | PHA | Australian government policy on intellectual property and its impact on the Australian healthcare system | State, Dept of (DOS) | 0 | 0 | 2015-04-08T23:23:14.047000-04:00 | ||
| 1657554 | CAPITALHILL ADVISORY a3f46420-bfe2-4735-afeb-23effd131ba1 | Q1 | CAPITALHILL ADVISORY | 401103351 | PFIZER AUSTRALIA PTY LTD | 2015 | first_quarter | PHA | Australian government policy on intellectual property and its impact on the Australian healthcare system | State, Dept of (DOS) | 17650 | 0 | 0 | 2015-04-08T23:24:15.373000-04:00 | |
| 1657558 | CAPITALHILL ADVISORY 18fb3b53-b7e3-454e-a127-07e20730927c | Q1 | CAPITALHILL ADVISORY | 401103351 | SANOFI-AVENTIS AUSTRALIA PTY LTD | 2015 | first_quarter | PHA | Australian government policy on intellectual property and its impact on the Australian healthcare system | State, Dept of (DOS) | 0 | 0 | 2015-04-08T23:25:16.497000-04:00 | ||
| 1657562 | CAPITALHILL ADVISORY e12fa3e4-7a12-4482-89ae-24a1e1b43114 | Q1 | CAPITALHILL ADVISORY | 401103351 | BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD | 2015 | first_quarter | PHA | Australian government policy on intellectual property and its impact on the Australian healthcare system | State, Dept of (DOS) | 0 | 0 | 2015-04-08T23:27:17.773000-04:00 | ||
| 1657564 | CAPITALHILL ADVISORY 45957393-5d19-4166-8fb0-dfde7a5432bf | Q1 | CAPITALHILL ADVISORY | 401103351 | MERCK SHARP & DOHME | 2015 | first_quarter | PHA | Australian government policy on intellectual property and its impact on the Australian healthcare system | State, Dept of (DOS) | 5000 | 0 | 0 | 2015-04-08T23:28:19.147000-04:00 | |
| 1657725 | RED+BLUE STRATEGIES 241ff137-0be4-4dd6-bf3b-0f6c408dd87a | Q1 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2015 | first_quarter | PHA | Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. Issues related to the treatment of pharmacy benefit managers in federal programs. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Issues related to access and affordability for prescription medications for both government and private sector benefit programs. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-04-09T12:05:04.293000-04:00 | |
| 1657726 | MR. VINCENT A. PANVINI 98c1a67a-bac4-47e5-abfa-7c4a4d3aabf5 | Q1 | MR. VINCENT A. PANVINI | 401008845 | PHRMA | 2015 | first_quarter | PHA | Medicare Part D Rebates Importation and Medical Innovation Act Trans-Pacific Partnership Patent Protections | HOUSE OF REPRESENTATIVES,SENATE | 5000 | 0 | 0 | 2015-04-09T12:06:05.510000-04:00 | |
| 1657858 | RED+BLUE STRATEGIES 994d2c5d-cdb8-4733-89a8-2038401500d4 | Q1 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2015 | first_quarter | PHA | S. 633 - The Promise for antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public. Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid. Advancing provisions to highlight Antibiotic Innovation in the President's FY 2016 budget. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-04-09T14:09:47.493000-04:00 | |
| 1657870 | RED+BLUE STRATEGIES 0fd5ee68-bec3-4a08-aef2-43cd90461108 | Q1 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2015 | first_quarter | PHA | CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-04-09T14:19:58.667000-04:00 | |
| 1658576 | PARRY, ROMANI, DECONCINI & SYMMS b8c910b2-0d8e-4bd8-a8df-9dd97bac832a | 1T | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | POZEN, INC. | 2015 | first_quarter | PHA | Support H.R. 2985, The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development. | HOUSE OF REPRESENTATIVES,SENATE | 24000 | 0 | 1 | 2015-04-10T15:01:49.377000-04:00 | |
| 1659062 | AARP ec5d127b-bed3-4e41-a65d-8ee0300947ad | 1A | AARP | 1694 | AARP | 2015 | first_quarter | PHA | Discussed the House Energy and Commerce Committee 21st Century Cures Initiative and Senate HELP Committee efforts focused on drug and medical device innovation issues. (no bill) Discussed the importance of potential savings to both consumers and the federal government of granting Secretarial negotiating authority to the HHS Secretary under Medicare Part D. (no bill) Discussed legislation to address Pay-for-Delay agreements used by drug manufacturers to block lower cost drugs from entering the market. Discussed the exclusivity period for biologic drugs. (no bill) Discussed biologic drug issues including implementation of the new approval pathway for biosimilar drugs. (no bill) Discussed other prescription drug issues and potential legislation on drug importation and "least costly alternative" payment for Part B drugs. (no bill) Discussed the need for data transparency on prescription drug research and development costs and drug prices, and enhanced data reporting on coverage determinations, exception, and redeterminations under the Part D appeals process. (no bill) | Centers For Medicare and Medicaid Services (CMS),Equal Employment Opportunity Commission (EEOC),Executive Office of the President (EOP),Federal Communications Commission (FCC),Federal Transit Administration (FTA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Trade Representative (USTR),Veterans Affairs, Dept of (VA),White House Office | 1860000 | 0 | 0 | 2015-04-13T10:45:53.880000-04:00 | |
| 1659400 | WILLIAMS AND JENSEN, PLLC ff485bd8-8a20-4f36-b97b-c1b9712f53e9 | Q1 | WILLIAMS AND JENSEN, PLLC | 41454 | FAGRON NORTH AMERICA | 2015 | first_quarter | PHA | Issues related to Drug Quality and Security Act (DQSA) and Pharmacy compounding. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2015-04-13T14:39:40.877000-04:00 | |
| 1659594 | NATIONAL RURAL HEALTH ASSOCATION 6af19dff-f455-4931-b12c-36f7d14148ec | Q1 | NATIONAL RURAL HEALTH ASSOCATION | 53048 | NATIONAL RURAL HEALTH ASSOCATION | 2015 | first_quarter | PHA | Support for 340B program | HOUSE OF REPRESENTATIVES,SENATE | 175000 | 0 | 0 | 2015-04-13T16:06:43.923000-04:00 | |
| 1659645 | AARP 5cfe5fae-7aaf-4ebf-a4dc-6ed32e448952 | Q1 | AARP | 1694 | AARP | 2015 | first_quarter | PHA | Discussed the House Energy and Commerce Committee 21st Century Cures Initiative and Senate HELP Committee efforts focused on drug and medical device innovation issues. (no bill) Discussed the importance of potential savings to both consumers and the federal government of granting Secretarial negotiating authority to the HHS Secretary under Medicare Part D. (no bill) Discussed legislation to address Pay-for-Delay agreements used by drug manufacturers to block lower cost drugs from entering the market. Discussed the exclusivity period for biologic drugs. (no bill) Discussed biologic drug issues including implementation of the new approval pathway for biosimilar drugs. (no bill) Discussed other prescription drug issues and potential legislation on drug importation and "least costly alternative" payment for Part B drugs. (no bill) Discussed the need for data transparency on prescription drug research and development costs and drug prices, and enhanced data reporting on coverage determinations, exception, and redeterminations under the Part D appeals process. (no bill) | Centers For Medicare and Medicaid Services (CMS),Equal Employment Opportunity Commission (EEOC),Executive Office of the President (EOP),Federal Communications Commission (FCC),Federal Transit Administration (FTA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Trade Representative (USTR),Veterans Affairs, Dept of (VA),White House Office | 1860000 | 0 | 0 | 2015-04-13T16:21:22.383000-04:00 | |
| 1659718 | PRINTING INDUSTRIES OF AMERICA, INC. afe08055-af87-4842-9fd3-2ea1471de9ca | Q1 | PRINTING INDUSTRIES OF AMERICA, INC. | 32203 | PRINTING INDUSTRIES OF AMERICA INC | 2015 | first_quarter | PHA | Pharmaceutical Printed Literature | Environmental Protection Agency (EPA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Labor Relations Board (NLRB),Occupational Safety & Health Administration (OSHA),SENATE,U.S. Postal Service (USPS) | 90000 | 0 | 0 | 2015-04-13T16:46:42.477000-04:00 | |
| 1659949 | ANIMAL HEALTH INSTITUTE 47ca5493-e1bc-4c3f-ab03-8dbec7c64b92 | Q1 | ANIMAL HEALTH INSTITUTE | 4037 | ANIMAL HEALTH INSTITUTE | 2015 | first_quarter | PHA | HR 639 and S 481 - Improving Regulatory Transparency for New Medical Therapies Act;Issues related to antibiotic research and data collection; | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-04-14T09:11:14.937000-04:00 | |
| 1660084 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS e1fe1f45-a644-4854-a593-efb950c3ba92 | Q1 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2015 | first_quarter | PHA | Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on labeling of genric medications and biosimilars. | Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 250000 | 0 | 0 | 2015-04-14T10:34:44.793000-04:00 | |
| 1660812 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION ad3e50e4-0d2d-4ac8-a00e-ad194a5d03ee | Q1 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2015 | first_quarter | PHA | Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2015-04-14T15:26:40.120000-04:00 | |
| 1660864 | CAPTURERX 37387a39-3fea-4305-b2f0-9e05c3514f64 | Q1 | CAPTURERX | 401103607 | CAPTURERX | 2015 | first_quarter | PHA | Advocating on behalf of the 340B prescription drug program. Promoting transparency and compliance within the 340B program. | Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-04-14T15:44:12.210000-04:00 | |
| 1661096 | UNIVERSITY OF IOWA c1618be2-6c56-47bb-b2e5-0fcad8321906 | Q1 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2015 | first_quarter | PHA | Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals | Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT) | 86662 | 0 | 0 | 2015-04-14T17:12:41.713000-04:00 | |
| 1661618 | KATE MOSS 89156c7a-6817-4d49-8240-68f4c486d4f4 | Q1 | KATE MOSS | 25988 | CVS HEALTH | 2015 | first_quarter | PHA | Issues related to prescription drug abuse and drug supply chain safety. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2015-04-15T11:30:41.827000-04:00 | |
| 1661868 | ACG ADVOCACY 528d4608-b580-44aa-b671-2fde604f6ebc | Q1 | ACG ADVOCACY | 2057 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2015 | first_quarter | PHA | Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-04-15T12:45:30.787000-04:00 | |
| 1662461 | CHRISTY ELLERBEE CONSULTING, LLC a9b6ef56-7b55-4364-800f-f610aacb566a | Q1 | CHRISTY ELLERBEE CONSULTING, LLC | 401103332 | INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.) | 2015 | first_quarter | PHA | Pharmaceutical issues relevant to Indivior, PLC. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2015-04-15T16:01:56.997000-04:00 | ||
| 1662552 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 39929c99-514e-4a29-bbb7-8025c000f57e | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2015 | first_quarter | PHA | issues related to the 340B drug discount program | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-04-15T16:42:03.870000-04:00 | |
| 1662567 | MCKENNA, LONG & ALDRIDGE b5a5e0f8-a7f5-48d5-b955-bb3a8af729b6 | 1A | MCKENNA, LONG & ALDRIDGE | 76913 | PURDUE PHARMA | 2015 | first_quarter | PHA | U.S. and Canadian regulatory policies regarding prescription drug abuse | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-04-15T16:53:13.483000-04:00 | |
| 1662653 | MR. GALEN RESER c8b12f44-f633-422e-9d24-37078907168d | Q1 | MR. GALEN RESER | 401055978 | PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS) | 2015 | first_quarter | PHA | Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. Monitored Fairness to Pet Owners Act. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-04-15T17:19:06.407000-04:00 | |
| 1663081 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. e73f77db-eb90-4758-b2d2-68177edfbc10 | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2015 | first_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 1600, Patients Access to Treatment Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE | 50000 | 0 | 0 | 2015-04-16T08:50:53.113000-04:00 | |
| 1663086 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. f45a8dcd-a6f6-4df2-8c3b-31498ee87307 | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2015 | first_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2015-04-16T08:53:54.377000-04:00 | |
| 1663100 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. aa2fd725-fefd-4641-bd11-5c6936cd7120 | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2015 | first_quarter | PHA | HR 1600, Patient Access to Treatment Act; HR 1801 Cancer Drug Coverage Parity Act/S. 1989 Cancer Treatment Parity Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30000 | 0 | 0 | 2015-04-16T08:57:58.373000-04:00 | |
| 1663285 | THE MADISON GROUP 1a82e482-0995-4185-9ee5-72e7236a98c9 | 1T | THE MADISON GROUP | 284050 | WEST-WARD PHARMACEUTICALS | 2015 | first_quarter | PHA | Issues pertaining to generic pharmaceutical drugs. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 1 | 2015-04-16T10:06:40.193000-04:00 | |
| 1663464 | APOTEX CORP. 9d3d0114-ddd1-45b1-9924-468195ce941a | Q1 | APOTEX CORP. | 310973 | APOTEX CORP. | 2015 | first_quarter | PHA | FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; House Energy & Commerce Committees 21st Century Cures discussion draft, provisions relating to federal policies regarding the discovery, approval and manufacturing of pharmaceuticals; Federal policy relating to International Nonproprietary Names for biosimilars; Federal policy relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, the Patient Protection and Affordable Care Act, and; Federal policy relating to the Implementation of Public Law 112-144, The Food and Drug Administration Safety and Innovation Act, Title 3, Fees Relating to Generic Drugs | HOUSE OF REPRESENTATIVES,SENATE | 160000 | 0 | 0 | 2015-04-16T10:54:22.933000-04:00 | |
| 1663883 | ENDO INTERNATIONAL d36f455f-1443-418b-a4b4-e28015804d7f | Q1 | ENDO INTERNATIONAL | 40011075 | ENDO INTERNATIONAL | 2015 | first_quarter | PHA | Issues related to tamper-resistant formulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act. | HOUSE OF REPRESENTATIVES,SENATE | 500000 | 0 | 0 | 2015-04-16T12:08:26.770000-04:00 | |
| 1663988 | RED+BLUE STRATEGIES 3b88fa3a-0c19-4489-8771-d7706731f065 | Q1 | RED+BLUE STRATEGIES | 400693064 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS | 2015 | first_quarter | PHA | Issues related to opioid abuse. Issues related to state-based marketplaces. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-04-16T12:26:18.623000-04:00 | |
| 1664021 | VALENTE & ASSOCIATES 5e1c5e00-4fb4-44c7-965a-1705706a63a1 | Q1 | VALENTE & ASSOCIATES | 45983 | SAV-MOR FRANCHISING, INC. | 2015 | first_quarter | PHA | Medicare Part D | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2015-04-16T12:35:34.817000-04:00 | |
| 1664137 | MASSACHUSETTS MEDICAL SOCIETY 00555ef8-5117-42e5-b7c9-c1a00a4cb302 | Q1 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2015 | first_quarter | PHA | S 320 - Medical Innovation Act - NIH funding | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 90000 | 0 | 0 | 2015-04-16T13:03:44.847000-04:00 | |
| 1664281 | JOHNS HOPKINS UNIVERSITY d4163990-afa3-422d-bf3f-6cb1f0fa0629 | Q1 | JOHNS HOPKINS UNIVERSITY | 20664 | JOHNS HOPKINS UNIVERSITY | 2015 | first_quarter | PHA | Pharmaceutical drug price increases; 340B drug discount program | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2015-04-16T13:41:53.723000-04:00 | |
| 1664346 | AMERICAN PHARMACISTS ASSOCIATION f3ac7b00-8167-4bde-ba76-23e91fbf2309 | Q1 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2015 | first_quarter | PHA | Reimbursement of pharmacist services - HR592/S314 Transitions of care Risk evaluation and mitigation services Track and trace/supply chain Health information technology Immunizations Compounding Tele-medicine Quality rating AMP FULs Biosimiliars Drug importation Generics labeling Preferred pharmacy network - HR793 Electronic labeling Home infusion - HR605/S275 21st century cures Precision medicine/pharmacogenomics Maximum allowable cost - HR244 | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) | 27243 | 0 | 0 | 2015-04-16T13:56:32.927000-04:00 | |
| 1664388 | SANOFI US SERVICES INC. 477341ea-fd17-4c65-86ff-943dc55843e9 | Q1 | SANOFI US SERVICES INC. | 56838 | SANOFI US SERVICES INC | 2015 | first_quarter | PHA | General issues related to the 340B Federal Drug Pricing Program | HOUSE OF REPRESENTATIVES,SENATE | 1370000 | 0 | 0 | 2015-04-16T14:04:55.713000-04:00 | |
| 1664579 | KENT & O'CONNOR, INC. 52e50494-43f8-451b-baae-189d43db7fc6 | Q1 | KENT & O'CONNOR, INC. | 21426 | INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION | 2015 | first_quarter | PHA | Legislation and regulations relating to drug and safety issues. | Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection | 20000 | 0 | 0 | 2015-04-16T14:47:33.583000-04:00 | |
| 1664796 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) b67e192f-ec83-4015-b44f-d6e7cfcc66c0 | Q1 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 400265214 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 2015 | first_quarter | PHA | Issues related to pharmaceutical pricing and federal oversight by the FDA | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 223020 | 0 | 0 | 2015-04-16T15:40:29.367000-04:00 | |
| 1664805 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 03e18e76-f87e-480a-8ff1-53a6643f908d | Q1 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2015 | first_quarter | PHA | H.R. 793 - Ensuring Seniors Access to Local Pharmacies Act of 2015; H.R. 244 - MAC Transparency Act of 2015; Congressional Oversight of 340 B Program; Fairness to Pet Act Legislation | Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE | 450000 | 0 | 0 | 2015-04-16T15:41:32.723000-04:00 | |
| 1665082 | 340B HEALTH 08309d12-981f-435f-90cc-b97287af4565 | Q1 | 340B HEALTH | 316434 | 340B HEALTH | 2015 | first_quarter | PHA | The 340B Drug Discount Program, HRSA's Mega-guidance and audits of covered entities, Fiscal Year 16 Labor-HHS Appropriations. | Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 258101 | 0 | 0 | 2015-04-16T16:55:13.623000-04:00 | |
| 1665101 | CAPITOL HILL CONSULTING GROUP 740d752a-514a-434c-ae5e-7edd93db4796 | Q1 | CAPITOL HILL CONSULTING GROUP | 72053 | PURDUE PHARMA LLP | 2015 | first_quarter | PHA | Controlled Drug Substances Act (21 USC 13) | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-04-16T17:01:26.943000-04:00 | |
| 1665118 | PD FRAZER CONSULTING, INC. 7d3c8ac6-4af9-4cd9-a149-c3752aea920f | Q1 | PD FRAZER CONSULTING, INC. | 65998 | CANADA INTERNATIONAL PHARMACY ASSOCIATION | 2015 | first_quarter | PHA | Monitor the development of proposed bills about the importation of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2015-04-16T17:13:38.820000-04:00 | |
| 1665213 | CALIFORNIA MEDICAL ASSOCIATION INC. 30b4a161-cb0f-4fa8-ac66-4a8d29c43a85 | Q1 | CALIFORNIA MEDICAL ASSOCIATION INC. | 40006052 | CALIFORNIA MEDICAL ASSOCIATION INC | 2015 | first_quarter | PHA | Curbing Opiod Abuse: Funding for State Prescription Drug Monitoring Programs and Increased funding for treatment. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 80000 | 0 | 0 | 2015-04-16T17:38:39.337000-04:00 | |
| 1665266 | INDEPENDENT PHARMACY COOPERATIVE aeec478b-980a-4388-aa3c-7945c7215601 | Q1 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2015 | first_quarter | PHA | H.R. 3204 Drug Quality and Security Act providing agency information on implementation and impact on the drug supply chain. H.R. 592/S. 314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas. H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-04-16T18:06:29.630000-04:00 | |
| 1665467 | EMPIRE CONSULTING GROUP d034ef68-4be2-4307-8263-2c839bc0c462 | Q1 | EMPIRE CONSULTING GROUP | 400703105 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2015 | first_quarter | PHA | Issues relating to the Medicare Prescription Drug Act; 340B Drug pricing program and drug pricing generally; patent reform proposals; S.320, Medical Innovation Act; funding for the National Institutes for Health; 2015 budget and Medicare Sustainable Growth Rate ("SGR"). | HOUSE OF REPRESENTATIVES | 40000 | 0 | 0 | 2015-04-16T22:35:36.883000-04:00 | |
| 1665657 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 5a5925d1-4238-4d6e-aef1-42a4455f8b65 | Q1 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2015 | first_quarter | PHA | Rx Pedigree (Public Law 113-54);Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953); Counterfeit Drugs; Importation of Prescription Drugs (S. 122) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 324000 | 0 | 0 | 2015-04-17T08:58:21.093000-04:00 | |
| 1665679 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) d4070e87-f909-4999-975d-cd3a8a6996b1 | 1A | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2015 | first_quarter | PHA | Rx Pedigree (Public Law 113-54);Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953, H.R. 592); Counterfeit Drugs; Importation of Prescription Drugs (S. 122) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 324000 | 0 | 0 | 2015-04-17T09:09:35.940000-04:00 | |
| 1666796 | ALKERMES, INC. 90fc80f1-b0c2-42c5-8564-866238eb05f8 | Q1 | ALKERMES, INC. | 400458235 | ALKERMES, INC. | 2015 | first_quarter | PHA | DEA regulatory transparency in controlled substances scheduling person DEA regulatory transparency in issuing research licenses and quotas | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) | 863000 | 0 | 0 | 2015-04-17T11:48:17.533000-04:00 | |
| 1666887 | NOVO NORDISK INC. 6e7dffc0-60df-493f-b1bc-3b6b0abb065e | Q1 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2015 | first_quarter | PHA | P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,U.S. Trade Representative (USTR) | 920000 | 0 | 0 | 2015-04-17T12:03:10.047000-04:00 | |
| 1667361 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 172d3c44-8664-4b8a-8823-7fa17255a750 | Q1 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015 | first_quarter | PHA | Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding. | Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE | 80000 | 0 | 0 | 2015-04-17T13:07:30.307000-04:00 | |
| 1667475 | CHAMBER HILL STRATEGIES 9ab225f5-a741-42f7-a72a-d6fa08fb403e | Q1 | CHAMBER HILL STRATEGIES | 400645947 | AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL) | 2015 | first_quarter | PHA | Implementation issues related to P.L. 113-54, the Drug Quality and Security Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-04-17T13:30:37.433000-04:00 | |
| 1667637 | BROWN RUDNICK LLP a171e1b3-13d4-44b8-b13d-e4e1948bdffe | Q1 | BROWN RUDNICK LLP | 287895 | APOTEX CORPORATION | 2015 | first_quarter | PHA | Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94) | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-04-17T13:56:58.747000-04:00 | |
| 1667642 | KOUNTOUPES DENHAM CARR & REID, LLC 81c40ae3-98b5-4bac-9c3a-ae74747d1713 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) | 2015 | first_quarter | PHA | Policy matters related to generic pharmaceuticals and biosimilars including naming, labeling, e-labeling, access and interchangeability and changes to the Risk Evaluation and Mitigation Strategies (REMS) program as well as issues related to Energy and Commerce Committee's draft on 21st Century Cures. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 60000 | 0 | 0 | 2015-04-17T13:56:59.713000-04:00 | |
| 1667734 | FTI GOVERNMENT AFFAIRS eff71688-1622-448b-ab8a-42ac77115f2b | Q1 | FTI GOVERNMENT AFFAIRS | 401054971 | PERRIGO, INC. | 2015 | first_quarter | PHA | Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. Monitored Fairness to Pet Owners Act. | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2015-04-17T14:07:43.967000-04:00 | |
| 1667778 | BROWN RUDNICK LLP 946ce27c-1ceb-4dd5-a4b6-83286c0937c8 | Q1 | BROWN RUDNICK LLP | 287895 | HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC | 2015 | first_quarter | PHA | Issues relating to Implementation of P.L. 113 - 54 (Drug Quality and Security Act); H.R. 471 & S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 480, H.R. 1725-relating to Prescription Drug Monitoring Programs; S. 524 & H.R. 953 relating to prescription drug abuse; S. 122 relating to importation of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-04-17T14:12:05.397000-04:00 | |
| 1667925 | ELI LILLY AND COMPANY a68a21c9-9005-4f00-a166-6005c4f359d8 | Q1 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2015 | first_quarter | PHA | Hospital discounts | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1830000 | 0 | 0 | 2015-04-17T14:23:12.370000-04:00 | |
| 1667945 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. 11a3f104-d376-4535-b42d-9ac608d853be | Q1 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 4653 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 2015 | first_quarter | PHA | Proposals relating to the regulation of direct to consumer prescription drug advertising | Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 410000 | 0 | 0 | 2015-04-17T14:24:17.277000-04:00 | |
| 1667948 | RED+BLUE STRATEGIES 7fae212b-0142-4c66-9939-26ae491b5018 | Q1 | RED+BLUE STRATEGIES | 400693064 | HOSPIRA | 2015 | first_quarter | PHA | Issues related to the naming of biosimilars as they enter into the national prescription drug marketplace. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-04-17T14:24:18.213000-04:00 | |
| 1667998 | BROWN RUDNICK LLP 77eb905e-b162-4614-8cb6-e044a55e4c16 | Q1 | BROWN RUDNICK LLP | 287895 | HOSPIRA, INC. | 2015 | first_quarter | PHA | Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94) | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-04-17T14:27:44.333000-04:00 | |
| 1668103 | BROWN RUDNICK LLP ce5faa67-d6fd-4956-913a-02fc27490b70 | Q1 | BROWN RUDNICK LLP | 287895 | PRIME THERAPEUTICS | 2015 | first_quarter | PHA | HR 793 - Ensuring Seniors Access to Local Pharmacies Act | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-04-17T14:32:20.877000-04:00 | |
| 1668130 | FTI GOVERNMENT AFFAIRS cec673e4-8bbc-45d6-a322-3d6b9758e475 | Q1 | FTI GOVERNMENT AFFAIRS | 401054971 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2015 | first_quarter | PHA | Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law). | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2015-04-17T14:33:30.653000-04:00 | ||
| 1668224 | BROWN RUDNICK LLP e66e36e6-55f8-4f80-aa77-1080097adaa5 | Q1 | BROWN RUDNICK LLP | 287895 | AMNEAL PHARMACEUTICALS | 2015 | first_quarter | PHA | Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); Issues relating to ANDA review and approval | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2015-04-17T14:40:21.757000-04:00 | |
| 1668303 | ARNALL GOLDEN GREGORY, LLP 435543c9-6edf-49af-b937-49b4a8e005cc | Q1 | ARNALL GOLDEN GREGORY, LLP | 400713137 | PHARMA AND BIOPHARMA OUTSOURCING ASSOCIATION | 2015 | first_quarter | PHA | FDA issues; Generic Drug Free User Act issues; small business relief legislation | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2015-04-17T14:44:50.237000-04:00 | |
| 1668326 | BROWN RUDNICK LLP 87d0e26e-ada2-494d-b971-f284f8736e60 | Q1 | BROWN RUDNICK LLP | 287895 | EXELA HOLDINGS, LLC | 2015 | first_quarter | PHA | Issues relating to ANDA review and approval | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2015-04-17T14:46:01.703000-04:00 | |
| 1668617 | KOUNTOUPES DENHAM CARR & REID, LLC 5e5b2e9d-8259-44c3-ad5a-ab12eb79fa4c | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2015 | first_quarter | PHA | General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. Issues related to "21st Century Cures" as well as FDA and NIH modernization. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 50000 | 0 | 0 | 2015-04-17T15:09:26.503000-04:00 | |
| 1668648 | BLUECROSS BLUESHIELD OF TENNESSEE f72b3c7f-02c2-4ee8-8082-b2c9caa8cd65 | Q1 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2015 | first_quarter | PHA | General Pharmacy Issues; specialty drug pricing | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2015-04-17T15:12:40.437000-04:00 | |
| 1668929 | CAPITOL HILL CONSULTING GROUP a609d730-6ba3-459c-85f4-19877576f2de | Q1 | CAPITOL HILL CONSULTING GROUP | 72053 | ENDO PHARMACEUTICALS | 2015 | first_quarter | PHA | Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825 | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2015-04-17T15:43:11.497000-04:00 | |
| 1669013 | CAPITOL HILL CONSULTING GROUP f6222f94-4a3d-42f2-a144-df9b11c416e1 | Q1 | CAPITOL HILL CONSULTING GROUP | 72053 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2015 | first_quarter | PHA | issues related to PL 113-54, The Drug Quality and Security Act issues related to agriculture appropriations | Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-04-17T15:56:02.370000-04:00 | |
| 1669074 | THORSEN FRENCH ADVOCACY LLC 07371a46-7243-47cd-bde2-ebb45b8005f1 | Q1 | THORSEN FRENCH ADVOCACY LLC | 400599826 | ASTRAZENECA PHARMACEUTICALS LP | 2015 | first_quarter | PHA | Issues related to access to pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-04-17T16:02:30.550000-04:00 | |
| 1669081 | CAPITOL HILL CONSULTING GROUP a495f724-865e-4538-8c13-c95b99a75053 | 1T | CAPITOL HILL CONSULTING GROUP | 72053 | BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS | 2015 | first_quarter | PHA | issues related to, but not limited to, pharmacy | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 1 | 2015-04-17T16:02:34.517000-04:00 | |
| 1669451 | SAFEWAY INC. 9f6dea50-ee81-40a6-9e9b-01e2d0ba23ef | Q1 | SAFEWAY INC. | 300173 | SAFEWAY | 2015 | first_quarter | PHA | H.R. 592/S. 314 -- Pharmacy and Underserved Areas Enhancement Act, all provisions. Preserve Access to Community Pharmacies in TRICARE (draft proposal, no bill number). | HOUSE OF REPRESENTATIVES,SENATE | 150000 | 0 | 0 | 2015-04-17T16:33:27.717000-04:00 | |
| 1669778 | UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY 30fa4175-4332-4e61-a963-627cc8cf42a1 | Q1 | UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY | 401097063 | UNIVERSITY HOSPITAL-NEWARK, NEW JERSEY | 2015 | first_quarter | PHA | --340B Program support to maintain current level of funding and discounts | HOUSE OF REPRESENTATIVES | 48642 | 0 | 0 | 2015-04-17T17:10:09.643000-04:00 | |
| 1669868 | GENENTECH, INC 8d0970bc-02ca-4fac-a783-b78a15b7d276 | Q1 | GENENTECH, INC | 15920 | GENENTECH INC | 2015 | first_quarter | PHA | Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies; 340(b) Drug Discount Program. | HOUSE OF REPRESENTATIVES,SENATE | 1310600 | 0 | 0 | 2015-04-17T17:19:49.787000-04:00 | |
| 1670146 | EVERGREEN ASSOCIATES, LTD. ee68b035-6a26-42c3-8b8a-0afa825f2a41 | Q1 | EVERGREEN ASSOCIATES, LTD. | 13984 | PHARMACEUTICAL PRINTED LITERATURE ASSOCIATION | 2015 | first_quarter | PHA | - Docket ID: FDA-2007-N-0363: Electronic Distribution of Content of Labeling for Human Prescription Drug and Biological Products - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016; Title VI- Related Agencies and Food and Drug Administration; Department of Health and Human Services, Food and Drug Administration | HOUSE OF REPRESENTATIVES,SENATE,Small Business Administration (SBA) | 10000 | 0 | 0 | 2015-04-17T18:01:18.443000-04:00 | |
| 1670399 | THE D MAJOR GROUP 04f115f5-d672-4451-a0c3-1afac9ea4da4 | Q1 | THE D MAJOR GROUP | 401103162 | CVS CAREMARK | 2015 | first_quarter | PHA | Issues related to preventing prescription drug abuse. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-04-17T21:23:23.813000-04:00 | |
| 1670422 | THE INGRAM GROUP LLC 21980d94-52b4-413a-8ac2-8abf51ff59ae | Q1 | THE INGRAM GROUP LLC | 400577737 | ELI LILLY AND COMPANY | 2015 | first_quarter | PHA | General issues related to the biopharmaceutical and pharmaceutical industries. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-04-17T21:48:44.310000-04:00 | |
| 1670575 | BLUESTONE STRATEGIES, LLC 5f58e9e9-e6e4-4e0c-9fde-6a1d748efbcf | Q1 | BLUESTONE STRATEGIES, LLC | 400658980 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2015 | first_quarter | PHA | Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues and 21st Century Cures legislation. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2015-04-18T09:59:38.850000-04:00 | |
| 1671337 | THE SIMMONS & RUSSELL GROUP, LLC 54c63fc3-b50f-4222-99c5-cfd50c66248d | Q1 | THE SIMMONS & RUSSELL GROUP, LLC | 401103235 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2015 | first_quarter | PHA | Drug importation and the FAIR Generics legislation; An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025, S.CON.RES.11. | SENATE | 60000 | 0 | 0 | 2015-04-19T10:59:20.230000-04:00 | |
| 1671524 | FLYNN & ASSOCIATES, INC. f56a1691-b524-4e73-8c36-ba6522f3a57e | Q1 | FLYNN & ASSOCIATES, INC. | 15020 | PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION | 2015 | first_quarter | PHA | Medicare Part-D rebates Trade agreements | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2015-04-19T14:07:32.877000-04:00 | |
| 1671790 | TEVA PHARMACEUTICALS USA, INC. 0b57f370-56a5-4f64-a750-d955711a9421 | Q1 | TEVA PHARMACEUTICALS USA, INC. | 76695 | TEVA PHARMACEUTICALS USA INC | 2015 | first_quarter | PHA | Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR) | 1200000 | 0 | 0 | 2015-04-19T17:54:50.173000-04:00 | |
| 1671919 | WINNING STRATEGIES WASHINGTON 5f5f950a-a89a-453f-b53a-2b1785db4da2 | Q1 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2015 | first_quarter | PHA | Pharmaceutical drug development, Reducing opiod overdose deaths and S. 707 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2015-04-19T18:51:07-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);